StemCells 21

What StemCells 21 does

StemCells 21 is a Bangkok-based regenerative medicine clinic that delivers personalized cellular therapy programs to international patients who travel to Thailand for treatment. The company administers pharmaceutical-grade Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs), MSC-derived extracellular vesicles (exosomes and microvesicles), and immune cell therapies, and offers complementary services including stem cell banking, supportive therapies, and a Precision Longevity Medicine program. All cellular products are produced in the company's own GMP pharmaceutical manufacturing laboratory within the SC21 Group, enabling end-to-end quality control from cell production through patient administration.

The business is structured around direct-to-patient medical tourism: prospective patients receive free no-obligation consultations via phone, video, or in-person, after which individualized treatment packages are quoted based on medical evaluation. The clinic serves three overlapping segments — international medical tourists, patients with chronic and degenerative conditions (osteoarthritis, multiple sclerosis, COPD, ALS, diabetes, cardiovascular, renal, hepatic, and autoimmune disease), and proactive longevity seekers — with multi-language support in English, Thai, Arabic, and Chinese. Go-to-market is sales-led and content-driven, with an extensive SEO-optimized blog and active social channels on Facebook, Twitter, Instagram, and YouTube. Pricing is quote-based and not publicly disclosed.

Operationally, StemCells 21 is the clinical patient-facing arm of SC21 Group, which also comprises SC21 Bio-Pharma Laboratories (GMP manufacturing), IntelliHealth (health services), and SC21 BioTech (biotechnology). The company is privately held, headquartered in Bangkok, Thailand, with a headcount in the 11-50 range, and claims over 15 years of clinical regenerative medicine experience. There is no disclosed external funding, no executive team detail available in the source material, and no publicly disclosed revenue.

Name

StemCells 21

Legal name

StemCells 21

Website

https://stemcells21.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

StemCells 21 is a Bangkok-based regenerative medicine clinic that delivers personalized UC-MSC, exosome, and immune cell therapies to international medical tourism patients seeking treatment for chronic, degenerative, and age-related conditions.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Services

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Regenerative medicine
• Stem cell therapy
• Cellular therapy services
• Exosome therapy
• Longevity medicine

Headquarters

HQ city

Bangkok

HQ country

Thailand

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Stem Cell Treatment Programs: Revenue generated from personalized regenerative medicine treatment programs. Each treatment program is individually designed by the medical team based on patient evaluation. Programs include UC-MSC therapy, immune cell therapies, extracellular vesicles (EVs), and longevity medicine programs.
2. Medical Consultations: Revenue from medical consultations including initial in-depth consultation to define treatment options, conducted via phone, video call, or in-person. Free no-obligation consultations are offered initially to qualify patients.
3. Stem Cell Banking: Revenue from stem cell banking services, allowing patients to store stem cells for future therapeutic use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

StemCells 21 operates a regenerative medicine clinic in Bangkok, Thailand delivering personalized stem cell treatment programs using pharmaceutical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs), MSC-derived extracellular vesicles (exosomes), immune cell therapies, and precision longevity medicine programs. The clinic is paired with an in-house GMP pharmaceutical manufacturing laboratory that produces the cellular therapies used in treatment, providing integrated quality control from laboratory to patient. International patients travel to Bangkok for individually designed treatment plans following detailed medical evaluation.

Product overview

StemCells 21 is a regenerative medicine company offering a portfolio of cellular therapy products and services centered on stem cell-based treatments. The core offering comprises pharmaceutical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treating degenerative diseases, injuries, and age-related conditions. The product line includes MSC Extracellular Vesicles (exosomes) as a cell-free alternative, alongside Stem Cell Banking for preservation services and Supportive Therapies for comprehensive care. Precision Longevity Medicine programs combine these cellular therapies with health optimization strategies. The company operates its own GMP pharmaceutical manufacturing laboratory, providing integrated quality control from laboratory to patient.

Differentiator

Problem solved

Functional benefit

Products and services

• Mesenchymal Stem Cell Therapy (UC-MSC) Personalized treatment programs using pharmaceutical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) for degenerative diseases, injuries, trauma cases, and longevity applications. Each program is individually designed by the medical team following detailed patient evaluation.
• MSC Extracellular Vesicles (Exosomes) Therapy Cell-free therapy using nanoscale vesicles (30-150 nanometres) secreted by mesenchymal stem cells, carrying proteins, lipids, RNA, and bioactive molecules that modulate inflammation, stimulate tissue repair, and support immune balance.
• Precision Longevity Medicine Personalized anti-ageing and longevity programs combining regenerative medicine with comprehensive health assessments, nutritional optimization, and lifestyle interventions designed to address individual ageing patterns and health optimization goals.
• Stem Cell Banking Preservation and storage service allowing patients to bank their stem cells for potential future therapeutic use.
• Supportive Therapies Complementary therapeutic modalities including nutritional counselling, targeted physical therapy, pain management strategies, and lifestyle modifications designed to support regenerative medicine outcomes.

Quantifiable outcome

• Measurable improvements sometimes within the first few days of treatment
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SC21 GroupcoreStrategic or Co-development PartnerStemCells21 is part of SC21 Group, which includes multiple entities: SC21 Bio-Pharma Laboratories (GMP pharmaceutical manufacturing), IntelliHealth (health services), and SC21 BioTech (biotechnology). SC21 Group provides the organizational structure and affiliated companies supporting StemCells21's regenerative medicine operations.
• SC21 Bio-Pharma LaboratoriescoreTechnology or IntegrationGMP pharmaceutical manufacturing laboratory within SC21 Group. Provides manufacturing infrastructure for pharmaceutical-grade stem cell and cellular therapy production, ensuring quality control from laboratory to patient.
• IntelliHealthminorOthersHealthcare services company affiliated with SC21 Group, part of the ecosystem of health-focused companies under the SC21 Group umbrella.
• SC21 BioTechminorOthersBiotechnology company affiliated with SC21 Group, part of the ecosystem of biotech-focused companies under the SC21 Group umbrella.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Global Stem Cells Group: Stem cell clinic operator and training provider with international locations; comparable in operating treatment clinics that administer cell therapies to medical tourism patients and in adjacent regenerative-medicine training/education revenue.
• Cryo-Cell International: US-listed cord blood and tissue banking company; comparable to StemCells 21's stem cell banking service line and its positioning around storage of biological material for future therapeutic use.
• Celltex Therapeutics: US/Mexico-based stem cell banking and autologous cell therapy clinic; directly comparable to StemCells 21 in operating a clinic that delivers MSC-based therapies to traveling international patients and in combining banking with clinical administration.
• Stem Cell Institute Panama (Cell Medicine): Panama-based regenerative medicine clinic offering stem cell therapy programs to international medical tourism patients, with a similar sales-led, free-consultation funnel and chronic-degenerative-condition treatment positioning.
• Beike Biotechnology: China-based stem cell technology and treatment provider running a network of partner hospitals offering UC-MSC and immune cell therapies; comparable business model (medical tourism + MSC therapies) at larger geographic scale.
• BioXcellerator: Stem cell clinic operating in Colombia with international medical tourism flow, offering MSC and exosome therapies; directly comparable as a boutique international regenerative medicine clinic competing for similar longevity and chronic-condition patients.
• Regenexx: US-based network of clinics specializing in orthopedic regenerative medicine including cell-based therapies; comparable in being a multi-clinic operator focused on cell therapy delivery to chronic-condition patients.

Broad incumbents

• Mesoblast: Clinical-stage biotech developing mesenchymal lineage cell therapies for inflammatory and degenerative diseases; comparable MSC-platform focus but operating as a regulated drug developer rather than a treatment clinic.
• Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived cell therapies; comparable cell therapy platform but as a regulated drug developer with clinical trials, contrasting with StemCells 21's clinic-delivery model.

Regional players

• Cells4Life: UK-based cord blood and tissue stem cell banking service; comparable in offering stem cell banking for future therapeutic use but regionally focused in the UK/Europe rather than serving an Asia-based international patient base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/stemcells21
• YouTubeyoutube.com/@stemcells21
• Facebookfacebook.com/stemcells21
• Instagramstemcells21.com/sc21-facility/#
• LinkedInlinkedin.com/company/jai-communications-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemCells 21